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Abstract Hospitals in Thailand operate in a multiple insurance payment environment.
This paper examines (1) access to medicines and other medical technologies, (2) treatment
outcomes, and (3) efficiency in resource use, among beneficiaries of the three government
health insurance schemes in Thailand. Using 2003–2005 outpatient and inpatient data for
patients with three tracer diseases from three government hospitals, we find that utilization
of more expensive items differs between patients whose insurers pay on a closed- or open-
ended basis. Where new vs. conventional drugs are both available, patients whose insurer
pays on a fee-for-service basis tend to have greater access to new drugs, compared to patients
whose insurer pays on a capitated or case basis. Similar patterns were found where there are
options between originator versus generic drugs, drugs in different dosage forms, and more
versus less advanced diagnostic technologies. Effects of insurance payment are more pro-
nounced where price gaps among the medical technologies are significant. Efficiency results
are mixed, depending on nature of the disease conditions and type of resources required for
treatment.




For the majority of the uninsured, the Thai government’s introduction of the 30 Baht Health
Care Scheme in 2001 substantially changed access to health services. The scheme also
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changed the way most hospitals are reimbursed for services. The new 30 Baht Scheme was
initiated to provide coverage to all citizens not eligible for any other public sector health
insurance program, and thus moved Thailand toward its goal of universal health coverage.
The 30 Baht Scheme, which is the largest insurance program in the country, covers approx-
imately 48.4 million people, or 76.6% of the population (National Statistics Bureau 2007).
The scheme is funded entirely by general taxes. It pays hospital outpatient services based on
the number of registered patients. For inpatient services, the diagnostic-related group (DRG)
method is used. Payment for drugs is included in the per-person and DRG rates. In addition,
the scheme also pays per item for a small number of high-cost diseases.
The 30 Baht Scheme operates alongside two other major public schemes of health security:
the Social Security Scheme (SSS) and Civil Service Medical Benefits Scheme (CSMBS).
The SSS covers private business employees, which number about 8 million. It is financed
by equal contributions from employees, employers, and the government. Payment to con-
tracted hospitals is made on a capitation basis and covers outpatient and inpatient services.
Additional utilization-related payments, with ceilings, are made for a limited number of
diseases.
The CSMBS is a government fringe benefit package that pays for health services used by
government employees and their dependents. Beneficiaries number about 6 million people.
The scheme is financed by taxes. Previously, the CSMBS paid both outpatient and inpatient
services on a fee-for-service basis. After a multiyear attempt to change the payment rules,
the DRG method was effectively instituted for paying inpatient services in 2007. Outpatient
drugs are now paid per item and outpatient services per service, while the costs of inpatient
drugs are included in the DRG payment.
A large number of people buy private insurance to either supplement or supplant the
benefits of the public programs they are eligible to join. Approximately 1.5 million people
have private health insurance benefits. Since private health insurance is voluntary, those who
choose to enroll pay a premium to insurance companies. Such companies generally pay on
a fee-for-service basis. This means that pharmaceuticals are paid per item (Ratanawijitrasin
2005).
Since Thai hospitals were long paid on a fee-for-service basis, the introduction of the 30
Baht Scheme caused a major shift in the hospital environment; now, services to the largest
segment of the population are paid on a closed-end basis (as defined by Jegers et al. 2002).
Currently, private health insurance and CSMBS outpatient services are reimbursed by ser-
vice. Because the three major public health insurance systems and private health insurance
employ different methods to pay for health services, hospitals in Thailand confront a mix of
financial incentives when managing their service provision.
Almost all hospitals provide services to the beneficiaries of these different insurance sys-
tems. Facing multiple payment incentives, many hospitals set prescribing and dispensing
guidelines that differ by insurance scheme. These commonly include cost-control mecha-
nisms for certain services delivered on a closed-end basis. Examples of such restrictions
include: “Prescribe only medicines listed in the National Essential Drug List (NEDL) to
patients in the capitation payment group, “No prescription of ‘medicine X’ for capitation
patients,” “Substitute generic drugs for capitation patients,” “Dispense only a three-day sup-
ply of drugs when discharging patients under any case-based payment system,” and “Hos-
pital director’s approval needed before using MRI for 30 Baht patients.” Hence, services—
including the prescription of medicine—might differ across insurance systems, even for
patients with the same condition.
Such rules are the behavioral response of health providers operating under multiple health
insurance plans with differing payment incentives. Unfortunately, aside from anecdotal
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accounts of how some hospitals have tried to influence resource utilization, no systematic
survey has documented the type and extent of these hospital policies and rules.
Closed-end payments seek to provide financial incentives for health care providers to
deliver services more efficiently. How payment incentives actually influence efficiency, and
how they affect service utilization, have been issues of debate in health policy. A large num-
ber of empirical studies in different countries show that financial incentives associated with
open-end payment methods lead to more health service utilization—both in terms of quantity
and type—while closed-end payment methods lead to less utilization. Reviews of studies on
the effects of health insurance financial incentives find that most compare certain utilization
variables across diseases and patients. A few are same-disease studies, which allow more spe-
cific evaluation of patients who need comparable care. Few studies focus on health outcomes
(Chaix-Couturier et al. 2000; Petersen et al. 2006; McCall et al. 2003).
In Thailand, recent reform has changed the environment in which hospitals operate.
Whether and how this change affects the use of health resources at the macro and micro
levels, as well as what health outcomes it has produced, are important policy questions. So
far, only a few studies provide empirical evidence on this issue, and none evaluate health
outcomes.
This article sets out to examine resource utilization patterns and health outcomes under
the multiple payment methods in Thailand. It focuses on assessing (1) access to medicines
and other medical technologies, (2) treatment outcomes, and (3) efficiency in resource use
among beneficiaries of the three government health insurance schemes in Thailand.
Methodology
This study employs a same-disease approach to compare health service utilization and out-
comes based on clinical practice guidelines. Three tracer conditions are used to capture
utilization patterns across a range of payment methods and points of service. Hospital data
between fiscal years 2003 and 2005 derive from electronic databases and paper medical
records.
Range of provider payment methods
Because of the changes in payment methods over the years, we first describe the specific
methods employed by each system during the study timeframe. For the time period covered
by this study, CSMBS paid on a fee-for-service basis for both outpatient and inpatient ser-
vices. The use of the DRG method for inpatient services, without overall budget limits, was
announced in 2001 and officially implemented in July 2007.
The 30 Baht Scheme calculates a budget for paying medical services per person, per year.
The overall capitation rate is then deducted for categories of payment such as inpatient,
emergency care, prevention, promotion, a administration costs for the center and provincial
agencies (and percentage of personnel salaries for government hospitals)—before disburse-
ment to providers. The per-person payment rate to government hospitals varies by hospital.
The overall rate per person, before deductions, was 1,308 Baht (approximately $37) in 2004.
Several payment methods, all closed-end, were employed:
1. A capitation rate for outpatient services In 2004, the mid-point of the study period, each
of the three hospitals in the study received a different amount per person per year for
outpatient services: 510 Baht (approximately $15), 484 Baht ($14), and 450 Baht ($13).
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2. A per-item payment for outpatient treatment of a limited number of high-cost diseases
In 2003 the scheme paid per item per year, with a ceiling of 30,000 Baht per person per
year (approximately $857) for cancer. In 2004–2005 this was changed to per item per
visit, with a ceiling of 4,000 Baht per visit (approximately $114).
3. DRGs with a global budget for inpatient services.
SSS also uses closed-end payment methods. It pays capitation for all outpatient and inpatient
services (at the same rate for all hospitals). In addition, it also pays per item per year, with a
ceiling for the treatment of certain high-cost diseases in both outpatient and inpatient cases.
Tracer conditions
In order to compare the different health insurance schemes, we evaluated specific utilization
rates and outcomes at the disease level using tracer conditions. A disease condition to be
selected as tracer for this study must satisfy the following requirements:
1. The disease conditions are commonly found in hospitals in Thailand.
2. The disease conditions require drug therapy.
3. The disease conditions reflect the type of payment categories and point of service under
study.
• Payment categories general and high cost/catastrophic diseases.
• Point of service outpatient visit only, inpatient admission only, and both outpatient
and inpatient visits.
4. The disease conditions must be classified within the system of International Classifica-
tion of Diseases—version 10 (ICD-10)—so that their data are retrievable from hospitals’
computerized information systems and are comparable.
5. Because medical records for many disease conditions lack detailed diagnosis and treat-
ment information, which makes assessment impossible, this study requires that the dis-
ease conditions must have the relevant outcome and cost data available.
6. The disease conditions can be clearly diagnosed and do not have complicated patterns
of comorbidity. This is to simplify the process of outcome assessment.
Three disease conditions were identified for this study. They are acute upper gastrointes-
tinal bleeding (AUGIB), epilepsy, and lung cancer.
AUGIB can be clearly diagnosed, has clear clinical guidelines, and requires inpatient
admission and a short duration of treatment. This condition is classified as a general disease
in the payment systems. Only inpatient admission cases were studied.
Epilepsy can also be clearly diagnosed, requires drug therapy, and has the clear treatment
goal of helping patients become seizure free. Patients suffering from epilepsy need long-term
care, which normally includes both outpatient and inpatient services. Epilepsy also belongs
to the general disease category for payment.
Lung cancer patients in the early stages of the disease (stages 1 and 2) are treated using
surgery, radioactive therapy, and chemotherapy. In this study, all lung cancer patients treated
by chemotherapy (drug treatment) were selected for the study on access to drugs. For the
efficiency evaluation, because unambiguous outcome data were needed, we selected only
those patients with non-small cell lung cancer in stages 3 and 4 whose treatment option is
limited to drug therapy. A patient in these two stages has a median survival of no more than
29 months, with an average of approximately 12 months depending on the choice of drug
regimen. This tracer is a high-cost disease (Table 1).
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Standards for diagnosis and drug therapy
Standard treatment guidelines issued by relevant professional societies were used for evaluat-
ing practice patterns. This study focused on the key recommendations for required minimum
standards of care for each tracer condition. The recommendations are provided below.
1. AUGIB Clinical guidelines (Gastroenterological Association of Thailand 2004) require
that diagnosis be determined by gastroscopic imaging and inpatient admission; the drug
of choice is any proton pump inhibitor (PPI).
2. Epilepsy Anti-epileptic drugs are adjusted to achieve the goal of being seizure free. Clin-
ical guidelines (Epilepsy Society of Thailand 2004) indicate the use of an anti-epileptic
drug appropriate for treatment. Conventional anti-epileptic drugs, although effective,
usually cause serious adverse drug reactions (ADRs). Newer drugs offer better efficacy
and fewer side effects, but cost more.
3. Lung cancer (National Cancer of Thailand and Department of Medical Service 2005)
The disease can be definitively diagnosed using computerized tomographic (CT) scan-
ning or magnetic resonance imaging (MRI). Drug treatment regimens can be chosen
from various combinations of anti-neoplastic drugs.
New generation anti-neoplastic drugs, which are more expensive, are also more effective
in stemming symptoms and aiding patient survival.
Patients treated with anti-neoplastic drugs, both old and new, suffer from severe side
effects such as nausea, vomiting, and anemia. To lessen these side effects, palliative drugs
such as anti-emetics and granulocyte colony stimulating factors (G-CSF) can be considered
for the management of ADRs. The costs of these drugs, particularly G-CSF, are high.
Treatment outcomes
Standard treatment guidelines issued by the relevant authorities were used as the basis for
evaluating desired outcomes. Key measurable outcome variables used in the evaluation for
the tracer diseases are as follows:
1. AUGIB The desired outcome, or cure, is defined as complete stoppage of bleeding. Infor-
mation on the bleeding condition was indicated in the gastroscope results and medical
records. Outcomes were determined at the point of discharge.
2. Epilepsy Becoming seizure free is the desired outcome of epilepsy treatment. In this
study, a patient is considered seizure free if, from the medical record, he or she had no
seizure symptoms in the past year.
3. Lung cancer Two criteria determine whether desired treatment outcomes of lung cancer
were achieved in this study: (a) the patient responded to anti-neoplastic treatment—that
is, there was no metastasis to other organs, such as the brain or liver, after the comple-
tion of anti-neoplastic treatments; and (b) the patient survived at least one year after the
anti-neoplastic treatments. Drop-out cases were excluded from the analysis.
Drug costs
Each hospital purchased its own medicines and set its own service charges. Therefore, the
costs of drugs and services differ by hospital. In this study, the charges of the largest of the
three hospitals were used as a reference point for calculation. Procurement costs were iden-
tified for each individual drug product with the same brand and generic name, dosage form,
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Does your health care depend on how your insurer pays providers? 159
Table 2 Relevant drugs for the tracer conditions included in the analysis
AUGIB Epilepsy Lung cancer
1. Alimentary drugs
• Proton pump inhibitor
• Antacid
• H2 blocker
• Others, e.g., antispasmodics
2. Intravenous and other
sterile solutions
• IV fluid


















2. New antineoplastic drugs:
e.g., gemtarabine






and strength. For services, since cost figures were unavailable, a charge for each individual
procedure was used.
Total drug costs per case were defined as costs of all required drugs given during the
duration of treatment, as detailed below.
1. AUGIB A patient with AUGIB arrives in a hospital emergency room (ER) and is then
admitted as an inpatient. The duration of treatment is defined as the time from the first
hospital contact for that episode till the time of discharge.
Any of the drugs used in the treatment of this particular condition was included. Relevant
drugs are categorized in Table 2. Drugs given for purposes other than the treatment of
AUGIB were excluded from the calculation. Total drug costs per case consist of drugs
used for the entire episode, from the first hospital contact point—the ER—till discharge,
including take-home medications.
2. Epilepsy Since the key outcome is being seizure free for an entire year, the duration of
treatment for epilepsy was defined as a fiscal year—October 1–September 30. Relevant
drugs for this condition are anti-epileptic drugs.
3. Lung cancer Relevant drugs used in the cost calculation are listed in Table 2.
Data sources
Study sites
Data were collected from three government hospitals. The first is a medical school in the
capital, Bangkok, with a 1,200-bed capacity. The second is a large general hospital (provin-
cial level) with a 500-bed capacity. The third is a general hospital in a different province
with a 200-bed capacity. The two latter hospitals are located in two separate provinces in the
northeastern region of Thailand.
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Electronic databases
Hospital electronic diagnosis and drug dispensing databases were used as data sources. The
records were available on an individual patient level. Data from the entire patient populations
of the three hospitals, which satisfied the inclusion criteria, from three fiscal years—October
1, 2002, to September 30, 2005—were retrieved for this study.
The data include patient demographics, health insurance benefits, items and costs of pre-
scribed drugs, and treatment procedures.
Paper medical records
Information on patient outcomes was not available from the computerized hospital informa-
tion system. Medical records in paper form were the only data source for such information.
Using patient hospital numbers from the electronic databases, samples of paper medical
records were drawn for the analysis.
Inclusion and exclusion criteria
Inclusion criteria
Included in the study were patients who had: (1) been diagnosed as having the tracer disease,
according to the pertinent ICD10; (2) visited or admitted to any of the three hospitals under
study between October 1, 2002, and September 30, 2005; and (3) received relevant drug
therapy for the tracer disease.
An epileptic patient must have been treated with anti-epileptic drugs for no less than
90 consecutive days (to qualify as suffering epilepsy as a chronic condition rather than an
occasional one). An AUGIB patient must have been admitted to the hospital as an inpatient.
Exclusion criteria
Data of patients with the following attributes were excluded from the study.
1. Patients who were covered by more than one health insurance benefit scheme between
October 1, 2002, and September 30, 2005 were excluded. This means, for example, that
beneficiaries of one government health insurance system who also bought private health
insurance, and those who switched from SSS coverage to the 30 Baht Scheme due to
job loss were excluded.
2. Patients whose medical records did not contain complete clinical outcome data for eval-
uation.
3. For patients with epilepsy, transaction data of hospital visits with anti-epileptic drugs
less than 90 consecutive days, and patients diagnosed as purely status epilepticus or
who had obtained only anti-epileptic injection drugs (likely to be acute cases), were
excluded.
The protocols for selecting transaction data of each of the three tracer diseases are sche-
matized in Fig 1.
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Fig. 1 Steps taken in the selection of transaction data for tracer diseases
Population and samples
In Fig 1, the selection steps in the first box, dealing with electronic patient databases, yield
transaction data for patients who satisfied the inclusion criteria. Cases selected in this group
were used to analyze access to drugs and services.
Evaluation of treatment effects relied on outcome data retrieved from paper medical
records. For AUGIB and non-small cell lung cancer, because of the smaller number of
qualified cases in the 30 Baht Scheme and the SSS, medical records for all cases identified in
the electronic database were retrieved; random samples of CSMBS cases were drawn using
123
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Table 3 Number of cases used in the analysis
Tracer Number of patients 30 Baht SSS CSMBS Total
Scheme
AUGB Number of cases from
e-database
41 18 320 379
Number of cases with
complete outcome data
29 13 160* 206
Epilepsy Number of cases from
e-database
116 68 729 913
Number of cases with
complete outcome data
89* 62* 288* 439
Lung cancer Number of lung cancer
patients from e-database
42 31 260 333
Number of non-small cell
lung cancer patients
(stage 3-4) from paper
medical records
21 7 102* 130




17 5 67 89
Note: * Random samples
Krejcie and Morgan’s (1970) table. For epilepsy, samples were drawn from cases in all three
health insurance systems using the proportional random sampling method. Sample size was
based on Krejcie and Morgan (1970). These cases were then checked for outcome data, and
those with the required level of completion were used in the study.
Analysis
Drug and service utilization patterns were examined to compare access to certain medical
technologies and the efficiency of resource use among the beneficiaries of the three govern-
ment health insurance systems. The analysis of access to medical technologies focuses on
the use of new drugs, palliative drugs, drugs in oral versus injectable forms, originator versus
generic products, and high-cost diagnostic procedures, following the practice procedures for
each of the tracers. Efficiency of resource utilization was compared using a cost-effectiveness
evaluation.
Utilizations and outcomes were analyzed using Chi-Square, with Monte Carlo correction
for cells having a value lower than 5. Difference of costs among the three groups were tested
using one-way analysis of variance (ANOVA).
Results
The number of cases included in the analysis, according to the selection criteria, is summa-
rized in Table 3. Records of patients in the electronic databases were used to assess access
to medical technologies, including drugs. Paper medical records with complete outcome
data, as required, were used to evaluate resource utilization efficiency and the corresponding
electronic records. Note that we made use of lung cancer cases in the access analysis, and
non-small cell lung cancer cases in the efficiency analysis.
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Table 4 Utilization of required drugs in AUGIB
Tracer disease Access to Health insurance payment methods Results
30 Baht
Scheme (%)
SSS (%) CSMBS (%) p value
AUGIB Required
drug
PPIs 41 (100) 18 (100) 319 (99.69) 0.912
PPIs (oral
form)




21 (51.22) 12 (70.59) 266 (83.13) 0.000
Originator’s
PPIs
22 (53.66) 12 (70.59) 271 (85.49) 0.000
Table 5 Access to new drugs and palliative drugs in epilepsy and lung cancer
Tracer disease Access to Health insurance payment methods Results
30 Baht
Scheme (%)
SSS (%) CSMBS (%) p value
Epilepsy New drug Anti-epileptic
drug




14 (93.33) 9 (69.23) 0 (0) –
Lung cancer New dry Anti-neoplastic
drug




5 (62.50) 0 (0) 0 (0) –
Lung cancer Palliative drug Anti-emetic drug 38 (90.48) 27 (87.10) 235 (90.38) 0.329
Originator’s
anti-emetic drug
3 (7.14) 2 (6.45) 154 (59.23) 0.000
G-CSF 0 (0) 4 (12.90) 30 (11.54) 0.073
Access to medical technologies
Required drugs
As shown in Table 4, there is no difference among the three health insurance systems in the
case of patients suffering AUGB; a PPI is the required drug, according to clinical practice
guideline. But CSMBS patients are more likely to receive the drug in injection form, as well
as originator products, than patients in the closed-end schemes.
New drugs
The percentages of epileptic and lung cancer patients prescribed new drugs differ signif-
icantly across the health insurance schemes (Table 5). Patients in the closed-end payment
schemes were less likely to receive new drugs than those in the open-end scheme. Only 13%
of patients in the 30 Baht Scheme and 19% in the SSS received new drugs, while 31% of those
in the open-ended CSMBS received new drugs for treatment. For lung cancer treatment, the
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Table 6 Access to required diagnostic procedures
Tracer disease Diagnostic Health insurance payment methods Results
procedure
30 Baht Scheme (%) SSS (%) CSMBS (%)
AUGIB Gastroscope 22 (53.56) 10 (55.56) 218 (68.55) 0.110
Lung cancer CT scan/ MRI 25 (59.52) 11 (35.48) 194 (74.62) 0.000
difference is even greater. New drugs were prescribed to 67% of CSMBS patients, compared
with 19% and 10% of 30 Baht and SSS patients, respectively.
Further analysis reveals that of the 15 patients in the 30 Baht group prescribed new anti-
epileptic drugs, 14 paid for the new drugs out of pocket. Similarly, 9 out of 13 of the SSS
group also paid out of pocket. For those covered by the CSMBS, all could get drug costs
reimbursed. Prescribing for the new anti-neoplastic drugs follows a similar pattern: 5 out of
8 patients in the 30 Baht Scheme treated with new drugs bought the drugs on their own.
These findings suggest that even among people covered by the same health insurance
system, unequal access to new drugs might still exist, depending on whether a patient pays
out of pocket.
Palliative drugs
Almost all lung cancer patients who received chemotherapy had anti-emetics drugs prescribed
with no difference among schemes. Approximately 12% of SSS and CSMBS lung cancer
patients were given G-CSF, while none of the 42 patients in the 30 Baht group received the
drug, although the difference was not tested significantly.
Additional analysis into whether there was a difference in prescription of originator versus
generic products shows a statistically significant difference with much higher percentage of
CSMBS beneficiaries (59%) receiving originator, and thus more expensive, drugs than those
in the other two schemes (7% and 6%).
High-cost diagnostic procedures
AUGIB patients in all three health insurance programs had about the same chance of being
diagnosed using gastroscopic imaging. By contrast, fewer lung cancer patients in the programs
with closed-end payment received an MRI or a CT scan, both high-cost procedures (Table 6).
The price differences of the different types of medical technologies are shown in Tables 7
and 8. When hospitals are paid on a closed-end basis, it is financially rewarding to restrict
access to drugs and services, especially high-cost items. The rationale of service management
appears self-explanatory. It also raises the question of how practice patterns affect quality of
care.
Efficiency in resource use
1. AUGIB The cost of medicines used to treat CSMBS patients was the highest among
the three groups. Because there was no significant difference in the effectiveness of
treatment, its cost-effectiveness for pharmacotherapy was then the lowest among the
three. Further analysis was done to gauge the severity of the patient condition, identified
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Table 7 Costs of key drugs in various categories used in the tracer conditions
Type of drugs Pharmacological group Drug cost: Baht
New versus
conventional drugs
Anti-epileptic drugs New drug lamotrigine 100 mg
tablet: 31.49
Conventional drug phenytoin
100 mg capsule: 1.92
Anti-neoplastic drug New drug gemtarabine 1 gm
inj.: 8767.58
Conventional drug




Alimentary drug Required drug omeprazole
20 mg capsule: 2.46
Other drug ranitidine 150 mg
tablet: 0.40






Alimentary drug Originator omeprazole 20 mg
capsule: 55.03
Generic omeprazole 20 mg
capsule: 2.46
Anti-emetic drugs Originator ondansetron 8 mg
Zydis: 314.58




Anti-emetic drugs Palliative drug ondansetron
8 mg: tablet 11.98
No drug 0
G-CSF Palliative drug granocyte 100
mcg: 1515.83
No drug 0
Table 8 Hospital charges for
diagnostic procedures required in
the tracer conditions








Non-small cell CT scan Chest X-ray
lung cancer 5000–8000 100
MRI Chest X-ray
8000–15000 100
according to relevant clinical criteria. It was found that the majority were serious cases,
and cost-effectiveness results still favor the closed-end schemes, as shown in Table 9.
Since drugs in the PPI category are therapeutically equivalent—that is, old and new drugs
in both oral and injection dosage forms have the same efficacy in inhibiting gastric acid
secretion—the use of cheaper drugs (old drugs and oral form) provide more value for
the money. But patients with gastrointestinal bleeding often suffer nausea and vomiting.
PPI injection has a value in reducing the trouble of swallowing the drug in oral form,
which helps lessen patient suffering. The analysis (Table 4) shows that larger percent-
ages of CSMBS patients were prescribed the injection drug than those in the closed-end
systems.
2. Epilepsy Drug costs per case were found to be surprisingly close between 30 Baht and
CSMBS patients, with the SSS patients costs highest. A significantly larger percentage
of CSMBS patients achieved the treatment goal of becoming seizure free. The open-end
CSMBS is then the most cost-effective system for this disease condition.
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Table 9 Cost and effectiveness of treating AUGIB cases, classified based on level of clinical risk
Health insurance payment methods
Closed-end Open-end
30 Baht Scheme SSS CSMBS
DRG Capitation Fee-for-service
Low clinical risk
# of cases 3 4 9
Cost 296.97 995.03 2,036.68
Effectiveness 100.00% 100.00% 100.00%
C/E ratio 296.97 995.03 2036.68
High clinical risk
# of cases 26 9 151
Cost 1,958.09 1,855.39 5,424.21
Effectiveness 96.15% 100.00% 96.00%
C/E ratio 2036.50 1855.39 5650.22
3. Non-small cell lung cancer Cancer is a high-cost disease. New generations of anti-neo-
plastic drugs are available at higher and higher prices. Treatment of 30 Baht and SSS
patients for non-small cell lung cancer, with the use of mainly conventional anti-neo-
plastic rather than new drugs, incurred significantly lower expenses than treatment of
CSMBS patients (Tables 4 and 10). The closed-end 30 Baht Scheme yielded the most
cost-effective results. But in terms of effectiveness, there were approximately 20% more
success cases in the CSMBS group.
Discussion
In emergencies involving gastrointestinal bleeding, patients in all insurance schemes received
the care required by clinical practice guidelines, with no significant association between the
method of provider payment and the required services. In this case, the availability of drugs
and equipment at moderate cost might also be beneficial to broad access.
By contrast, utilization of more expensive items differs between the closed- and open-end
systems. It seems that where new and conventional drugs are both available with a consid-
erable price gap, patients in a fee-for-service health insurance scheme tend to have greater
access to more expensive drugs. This pattern is also evident in cases of originator versus
generic drugs, drugs with different dosage forms, and more versus less advanced diagnostic
technologies.
What added value do these advanced medical technologies offer? The new anti-epileptics
render better control of seizures and have fewer side effects. As a result, 20% more CSMBS
patients became seizure free than those in the closed-end systems. For lung cancer, 20%
more CSMBS patients than those in the closed-end systems were able to live through their
next birthday with new generation anti-neoplastics. Note also that almost all patients in the
closed-end insurance schemes who took these new drugs paid for their drugs out-of-pocket.
With more prescriptions of PPI injections for AUGIB, patients probably enjoy a better quality
of life. Unfortunately, this study focused on clinical quality and did not include any measure
of quality of life in the analysis.
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Table 10 Drug costs and cost-effectiveness of treatment
Tracer Efficiency in resource use Health insurance payment methods
Closed-end Open-end







# of cases 29 13 160




# of cured cases 28 (96.55%) 13 (100.00%) 154 (96.25)
p value 1.000
Average drug cost (Baht) per
cured case
1,804.54 1,590.67 5,037.82
Capitation and DRG Capitation FFS
Epilepsy # of cases 89 62 288




# of seizure free cases 78 (77.23%) 49 (63.64%) 259 (90.24%)
p value 0.000
Average drug cost (Baht) per
seizure free case
7,318.29 14,416.76 6,623.55






# of cases 17 5 67




# of success case 7 (41.17%) 2 (40%) 41 (61.19%)
p value 0.317
Average drug cost (Baht) per
success case
115,533.03 151,233.09 262,942.76
Regarding the cost-effectiveness of pharmaco-therapy, it was found that average drug
costs for treating AUGIB and non-small cell lung cancer were comparable, but there was a
significant gap between patients in closed-end systems and those in the CSMBS. Since effec-
tiveness of AUGIB treatment did not differ among the groups, the closed-end programs were
more cost-effective than the open-end one. In the treatment of non-small cell lung cancer,
care rendered to CSMBS patients was more effective but less efficient due to the high cost
of cancer drugs.
In cases of epilepsy, which is a chronic condition, treatment cost more for the closed-end
SSS patients but with fewer seizure-free cases than in the CSMBS. In addition, the aver-
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age drug costs for CSMBS patients were about as those for 30 Baht patients. From a more
in-depth examination of the medical records, it was found that patients in the closed-end
payment schemes often began with conventional drugs. Due to the lower efficacy of the
conventional anti-epileptic medicines compared to the new ones, more drug items were then
added subsequently for these patients to control seizures. Adding together the costs of the
multiple items might be the reason for the higher overall costs. It appears that, in the attempt
to save costs, effectiveness and probably quality of life had to be compromised. Nonetheless,
we did not conduct in-depth analysis of the medical records on this additional aspect; the
point is more suggestive than conclusive.
Considering utilization patterns, available medical technologies, and concerns about costs
and effectiveness, a key question arises: How much is a society willing to pay for the health
care of its members? Or, more specifically, for what level of effectiveness and quality of life
is it willing to pay?
Another point worth pondering is that the analysis of AUGIB shows no difference in the
utilization of the required drug, PPI, while in the other two cases, drug utilization patterns
differ among groups. Taking into account the emergency nature of diseases like AUGIB and
the relatively non-urgent nature of other conditions, does this suggest that factors such as
the nature of a disease and its cure might play a role in medical decisions and modify the
effects of financial incentives? The common classification systems currently used to deter-
mine payment methods are based on crude criteria such as point of service, inpatient versus
outpatient, cost of input, and general versus high cost. Perhaps these criteria are better suited
to convenient rate calculation than to influencing health care efficiency. Designing better
payment methods that will help increase the effectiveness and efficiency of care requires
reconceptualization and more research and development.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommer-
cial License which permits any noncommercial use, distribution, and reproduction in any medium, provided
the original author(s) and source are credited.
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